Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Iterum Therapeutics ( (ITRM) ) has provided an update.
On September 10, 2025, Iterum Therapeutics held its annual general meeting where shareholders voted on several proposals. Notably, David Kelly was elected as a Class I director, while the appointment of KPMG as the independent registered public accounting firm was ratified. However, shareholders did not approve proposals related to executive compensation, authorized share capital increase, directors’ allotment authority, pre-emption rights opt-out, and an amendment to the equity incentive plan, indicating potential challenges in gaining shareholder support for strategic initiatives.
The most recent analyst rating on (ITRM) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Iterum Therapeutics stock, see the ITRM Stock Forecast page.
Spark’s Take on ITRM Stock
According to Spark, TipRanks’ AI Analyst, ITRM is a Underperform.
Iterum Therapeutics faces significant financial challenges with ongoing net losses and cash flow issues, despite positive developments such as FDA approval of ORLYNVAH. The technical indicators suggest weak market momentum, and valuation metrics reflect poor investment attractiveness. The potential market for ORLYNVAH and improved financial performance are notable positives, but strategic uncertainties and financial obligations weigh heavily on the stock’s outlook.
To see Spark’s full report on ITRM stock, click here.
More about Iterum Therapeutics
Iterum Therapeutics plc operates in the pharmaceutical industry, focusing on developing anti-infectives aimed at combating multi-drug resistant pathogens. The company primarily targets unmet medical needs in the treatment of serious infections caused by resistant bacteria.
Average Trading Volume: 815,937
Technical Sentiment Signal: Sell
Current Market Cap: $29.49M
Find detailed analytics on ITRM stock on TipRanks’ Stock Analysis page.